The success of PReCePT, a programme to increase the use of magnesium sulphate to prevent cerebral palsy in premature babies, has been highlighted in a new paper published in BJOG: An International Journal of Obstetrics and Gynaecology.

The paper shares the findings of the Health Foundation funded PReCePT study, part of the national PReCePT programme led by Health Innovation West of England (formerly AHSN) for the AHSN Network. It shows uptake of magnesium sulphate increased across all maternity units in England, regardless of whether they were given extra support.

The study, conducted by NIHR ARC West researchers, compared uptake in 27 maternity units under the standard programme with 13 units given an enhanced support package. Standard support included a PReCePT Quality Improvement (QI) guide and toolkit, support from local AHSNs and 90 hours of backfill for a midwife PReCePT champion. The enhanced support included the standard package plus unit-level QI coaching, a further 90 hours of midwife backfill and 104 hours of backfill for an obstetrics or neonatology lead, and other support.

The researchers found that in the year before the study started, 68% of eligible mothers in the control group and 64% of mothers in the enhanced support group received magnesium sulphate. After the study, this had gone up to 84% and 85% respectively. After adjusting for other factors, the two groups had improved by very similar amounts. The standard National PReCePT Programme (NPP) (control group) supported by AHSNs was the most cost-effective way to improve use of magnesium sulphate.

However, staff in the enhanced support group tended to understand the issues better and had better teamwork. This may be important because a 2022 review of poor care in the worst-performing maternity units in England found that a lack of teamwork was a significant contributory factor.

The research team also highlighted that the enhanced support package may have been the more realistically funded model, as many midwives put in extra time to support PReCePT. They say in the paper:

“This real implementation cost should not be underestimated in future improvement programmes. The high level of commitment, QI capacity and teamworking culture already present in some NPP units, and the high levels of interaction between trial arms (contamination), may also explain the overall similarity in outcome between groups.”

Karen Luyt, Professor in Neonatal Medicine at the University of Bristol, Chief Investigator for PReCePT and Consultant Neonatologist at St Michael’s Hospital, Bristol, said:

“The PReCePT randomised controlled trial has given valuable insights into how new treatments should be implemented into routine NHS clinical practice and how teamwork may be improved in NHS teams providing perinatal care. An intervention that can improve teamwork, is likely to have far-reaching benefits across a broad range of perinatal outcomes.”

Find out more about the PReCePT programme. 


Posted on September 19, 2023

> Back to index

  twitter   facebook   linkedin